ArticleFrontiers in parasitology2026
Differences in novel
Article in Frontiers in parasitology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Introduction: Schistosomiasis is a neglected tropical disease caused by parasitic worms of the genus Methods: We evaluated the performance of these RDT prototypes using serum, whole blood, and dried blood spots (DBS). RDT results were determined by two visual readers and a Lumos automated reader, which also provided a quantitative readout of test line intensity. Lumos results were used to quantify test line stability over time. Further, we compared RDT results to other serologic assays (ELISA and the multiplex bead assay) that detect antibodies against Sm25, Sm29 and two additional Results: While both Sm25 and Sm29 RDTs exhibited high specificity and stability that surpassed TPP criteria, their sensitivity fell short of TPP goals. Sensitivity was highest with serum, followed by DBS, then whole blood, which would be the most useful for point-of-care settings. In addition, we identified a gap in the ability of currently used recombinant antigens to detect all people infected with Discussion: Our findings underscore that while these prototypes represent a promising start, there is still a case for novel antigen discovery and generation of RDTs with increased sensitivity to meet TPP criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.